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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used for structuring this report [1]. The Model organ-
ises HTA information according to pre-defined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is ixazomib? 
A0022 Who manufactures ixazomib? 
A0007 What is the target population in this assessment? 
A0020 For which indications has ixazomib received marketing authorisation? 
Health problem and current use 
A0002 What is multiple myeloma? 
A0004 What is the natural course of multiple myeloma? 
A0006 What are the consequences of multiple myeloma for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of multiple myeloma? 
A0003 What are the known risk factors for multiple myeloma? 
A0024 
How is multiple myeloma currently diagnosed according to published guidelines and in 
practice? 
A0025 
How is multiple myeloma currently managed according to published guidelines and in 
practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of ixazomib on mortality? 
D0005 
How does ixazomib affect symptoms and findings (severity, frequency) of multiple 
myeloma? 
D0006 How does ixazomib affect progression (or recurrence) of multiple myeloma? 
D0011 What is the effect of ixazomib on patients ̕ body functions? 
D0012 What is the effect of ixazomib on generic health-related quality of life? 
D0013 What is the effect of ixazomib on disease-specific quality of life? 
Safety 
C0008 How safe is ixazomib in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying ixazomib? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of ixazomib? 
A0021 What is the reimbursement status of ixazomib? 
 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Ixazomib/Ninlaro
®
/L01XX50 
 
B0001: What is ixazomib? 
Ixazomib (Ninlaro
®
) is an orally bioavailable, reversible and selective pro-
teasome inhibitor [2-5]. It binds to the beta 5 subunit of the 20S proteasome 
and thereby inhibits its chymotrypsin-like activity. In vitro studies have 
shown that ixazomib induces apoptosis of multiple myeloma cell lines [2, 5].  
The recommended dose of ixazomib for one 4-week cycle (28 days) is 4 mg 
administered orally on days 1, 8, and 15. Treatment with ixazomib should be 
continued until disease progression or unacceptable toxicity [2]. 
 
A0022: Who manufactures ixazomib? 
Millennium Pharmaceuticals, Inc. (Takeda Oncology) 
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Ixazomib, combined with lenalidomide and dexamethasone, is indicated 
for the treatment of patients who are refractory to prior therapy or who 
exhibit relapsed as well as relapsed and refractory multiple myeloma 
(MM). 
 
 
 
4 Current regulatory status 
A0020: For which indications has ixazomib received marketing authorisa-
tion? 
Ixazomib, in combination with lenalidomide and dexamethasone, was ap-
proved by the US Food and Drug Administration (FDA) on 20 November 
2015 for the treatment of patients with MM who have received at least one 
prior therapy [2]. 
orally bioavailable, 
reversible and selective 
inhibitor of the 20S 
proteasome 
28-day cycle: 
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indicated for relapsed 
and/or refractory MM 
FDA approval for MM 
since 2015 
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In November 2016 ixazomib has received marketing authorisation by the 
European Medicines Agency (EMA) for the following indication: ixazomib 
in combination with lenalidomide and dexamethasone for the treatment of 
adult patients with MM who have received at least one prior therapy [6]. 
 
 
 
5 Burden of disease 
A0002: What is multiple myeloma? 
MM is a heterogeneous disease of various cytogenetically distinct plasma cell 
malignancies [7, 8]. Molecular characterisation and classification allows now-
adays to distinguish prognostic relevant subgroups, which will have increasing 
influence in the choice of treatment [9]. 
 
A0004: What is the natural course of multiple myeloma? 
MM is thought to arise from the malignant transformation of post-germinal 
centre plasma cells. This appears to be the consequence of a two-step model of 
progression. In the first step, an asymptomatic pre-malignant stage of clonal 
plasma cell proliferation termed monoclonal gammopathy of undetermined 
significance (MGUS) is established. In the second step different progression 
events can occur, such as dysregulation of cell cycle controls, escapes from 
normal apoptotic pathways, or changes in the stromal microenvironment 
which induces the malignant clonal proliferation that is characteristic of 
MM [8, 10, 11].  
Commonly, end organ damage, including hypercalcemia, renal dysfunction, 
anaemia, or lytic bone lesions are characteristics of MM. However, MM 
sometimes occurs in an intermediately asymptomatic manner or as a more 
advanced pre-malignant stage that is referred to as smouldering MM (SMM) 
[8, 10, 11]. 
 
A0006: What are the consequences of multiple myeloma for the society? 
Though MM is an orphan disease, the age peak in the early elderly age sug-
gests that rising numbers of patients will occur. In addition, the longer sur-
vival rates of affected people, due to new therapeutic options will be chal-
lenging future considerations on pharmacoeconomic consequences world-
wide, and especially in countries with ageing societies. Considering migra-
tion the differences between the ethnicities must also be taken into account 
[12, 13]. 
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A0023: How many people belong to the target population? 
In Austria, the incidence for plasmacytomas and plasma cell malignancies, 
including MM, is 3.0 per 100,000 persons per year (based on the WHO-
world population 2011). In 2012, 471 persons were newly diagnosed, of 
whom 245 were men and 226 were women. 1.2% of all malignant neoplasm 
cases in Austria are due to plasmacytomas and plasma cell malignancies. 
The survival rate (2010-2012) for three years after diagnosis is 58% [14]. My-
eloma is most commonly diagnosed between the ages of 65 and 74 (median 
age 69) [12]. 
 
A0005: What are the symptoms and the burden of multiple myeloma? 
Signs and symptoms in MM patients are mostly related to the infiltration of 
plasma cells into the bone marrow. For the diagnosis evidence of organ 
damage attributable to the clonal plasma cell disorder is necessary. The 
most common symptoms comprise fatigue with or without anaemia, bone 
pain, changes in electrophoreses (monoclonal proteins in serum and/or 
urine) and renal dysfunction. Rare but critical symptoms in the beginning of 
MM are hypercalcemia hyper viscosity syndrome or spinal cord compression 
[9, 15]. 
 
A0003: What are the known risk factors for multiple myeloma? 
Risk factors associated with MM are older age, body mass index (BMI), eth-
nicity and, in a small but unknown number of instances, family history. In 
addition, persons with MGUS or solitary plasmacytoma have a chance to de-
velop MM [9]. 
 
A0024: How is multiple myeloma currently diagnosed according to pub-
lished guidelines and in practice? 
The diagnosis of MM proceeds in accordance with the current criteria of the 
International Myeloma Working Group [16]. In addition to the evidence of 
≥ 10% clonal plasma cells in a bone marrow examination or a biopsy-proven 
plasmacytoma, the diagnosis of MM involves the presentation of monoclonal 
proteins in the serum and/or urine. For the diagnosis of symptomatic MM 
myeloma defining events (MDE) that comprise of defined CRAB (C = hy-
per calcemia, R = renal insufficiency, A = anaemia, B = bone lesions) fea-
tures are required [8, 17].  
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6 Current treatment 
A0025: How is multiple myeloma currently managed according to published 
guidelines and in practice? 
To stratify the risk of MM, the Mayo Stratification for Myeloma and Risk-
Adapted Therapy (mSMART) can be applied. This risk stratification also 
takes prior cytogenetic abnormalities, determined by a fluorescence in situ 
hybridisation (FISH), into account. It is classified in three different risk 
stages: high-risk, intermediate-risk and standard-risk. In addition, time to 
relapse should also be considered in risk determination. Depending on the 
result of the risk stratification, the subsequently described treatment options 
should be applied [18, 19].  
In patients who are eligible for autologous stem cell transplantation (ASCT) 
the following treatment options can be used [8, 17, 20]:  
 Lenalidomide low-dose dexamethasone (Rd) 
 Bortezomib-containing regimes (like bortezomib-
cyclophosphamide-dexamethasone [VCD], bortezomib-
thalidomide-dexamethasone [VTD]) 
 Carfilzomib-lenalidomide-dexamethasone (KRD) 
 Multi-drug combinations (multiagent combination chemotherapy, 
like bortezomib, dexamethasone, thalidomide, cisplatin, doxorubi-
cin, cyclophosphamide and etoposide [VDT-PACE]) 
To reduce toxicity, the low-dose dexamethasone regimen (40 mg weekly) is 
favourably used in all treatment regimens. It has not yet been established 
whether post-transplant maintenance therapy should be administered and 
which patient population should receive it. However, possible options are 
lenalidomide maintenance therapy or maintenance therapy with a pro-
teasome inhibitor (like bortezomib) [8].  
Treatment options for patients who are not eligible for ASCT are the follow-
ing: melphalan in combination with prednisone and thalidomide (MPT), 
bortezomib-based regimens (like VCD and VDT) and Rd. Subsequent 
treatment options are available for patients who have relapsed/refractory 
MM [8, 17, 18, 21]: 
 ASCT 
 Bortezomib- and lenalidomide-based regimens (like VCD and 
VDT) 
 Carfilzomib, lenalidomide and dexamethasone or dexamethasone 
alone 
 Pomalidomide and dexamethasone 
 Panobinostat, bortezomib and dexamethasone 
 Daratumumab 
Although, there is improvement of survival in patients with MM by disease 
control, eradication of the malignant plasma cell clone is still a rare event. 
Since, subsequent therapies increase the risk of development of resistance. 
Therefore, new drugs are still warranted, especially for MM subtypes with 
poor prognosis [22]. 
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7 Evidence 
A literature search was conducted on 25 October 2016 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “Ixazomib”, “mln9708”, “Ninlaro”, “multiple myeloma”, 
“plasma cell myeloma”, “relapsed” and “refractory”. The manufacturer who 
submitted six references (five of which had already been identified by sys-
tematic literature search) was also contacted. A manual search identified 15 
additional references (web documents and journal articles). Overall, 221 ref-
erences were identified. Included in this report are:  
 One phase III study, assessing the addition of ixazomib to lenalid-
omide and dexamethasone in the treatment of patients who have re-
lapsed, refractory, or relapsed and refractory MM [23, 24]. 
 One phase II study, assessing the safety, tolerability, and activity of 
weekly oral ixazomib combined with lenalidomide and low-dose 
dexamethasone in patients with newly diagnosed MM [25]. 
The methodological quality of the evidence was conducted to assess the risk 
of bias at the study level based on EUnetHTA internal validity for RCTs 
[26]. Evidence was assessed based on the adequate generation of randomisa-
tion sequence, allocation concealment, blinding of patient and treating phy-
sician, selective outcome reporting and other aspects that may increase the 
risk of bias. Study quality details are reported in Table 4 of the Appendix. 
 
7.1 Clinical efficacy and safety –  
phase III studies 
The TOURMALINE-MM1 trial, a randomised, double-blind, multicentre, 
placebo-controlled phase III study, was conducted to assess the addition of 
ixazomib to lenalidomide and dexamethasone for the treatment of patients 
who have relapsed, refractory, or relapsed and refractory MM [23, 24]. Alt-
hough follow-up is ongoing, the results of two pre-specified interim analyses 
are reported. Progression-free survival (PFS) and the overall response rate 
(ORR) were evaluated in the first analysis. The median follow-up at the time 
of the first interim analysis was 14.8 months in the ixazomib group and 14.6 
months in the placebo group. 129 events of disease progression or death oc-
curred in the ixazomib arm and 157 in the placebo group at the time of the 
first interim analysis. The second interim analysis was performed at a medi-
an follow-up of about 23 months. At this point in time, overall survival (OS) 
and adverse events (AEs) were analysed. At the time of the 23-month analy-
sis 171 deaths had occurred, 81 in the ixazomib group and 90 in the placebo 
group. 
A total of 722 patients were randomly assigned in a 1:1 ratio to either receive 
4 mg of ixazomib or a placebo on days 1, 8 and 15 of a 28-day treatment cy-
cle. Additionally, all patients received 25 mg of oral lenalidomide on days 1 
through 21 and 40 mg of dexamethasone on days 1, 8, 15 and 22. The strati-
fication of randomisation was based on the number of prior therapies, the 
prior treatment with proteasome inhibitors and the International Staging 
System disease stage. The median number of treatment cycles in the ixazo-
mib group were 17 (1-34) and 15 (1-34) in the placebo group. 
systematic literature 
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Enrolled patients had a median age of 66, and ranged from 30-91. The study 
population had an Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 0–2 and had received at least one prior therapy. Cytogenetic 
analyses were available for 76% of patients, 19% of whom had high-risk cy-
togenetic abnormalities. Detailed patient characteristics including inclusion 
and exclusion criteria can be found in Table 3. 
The primary outcome of TOURMALINE-MM1 was PFS; secondary out-
comes included overall ORR, OS, and PFS in patients with high-risk cyto-
genetic abnormalities. Other evaluated study endpoints were the change in 
global health status and safety. AEs were assessed according to the National 
Cancer Institute Common Terminology Criteria for AEs (NCI-CTCAE), 
version 4.03. 
 
7.1.1 Clinical efficacy 
D0001: What is the expected beneficial effect of ixazomib on mortality? 
At the time of the second interim analysis (23 months), the median OS had 
not yet been reached in either of the two study groups; follow-up is ongoing. 
At that time 171 deaths had occurred, 81 in the ixazomib group and 90 in 
the placebo arm. 
 
D0006: How does ixazomib affect progression (or recurrence) of multiple 
myeloma? 
PFS, the primary endpoint, was significantly improved (p = 0.01) in the in-
tention-to-treat population of the ixazomib group. The median PFS was 20.6 
months in the ixazomib group and 14.7 months in the placebo group. The 
hazard ratio (HR) for disease progression of ixazomib compared to placebo 
was 0.74 (95% CI 0.59–0.94). 
The median PFS for patients with high-risk cytogenetic abnormalities, of 
whom 75 patients were in the ixazomib group and 62 patients in the placebo 
group, was 21.4 months and 9.7 months respectively. The HR for disease 
progression among patients with high-risk cytogenetic abnormalities was 
0.54 (95% CI 0.32–0.92, p = 0.02) 
 
D0005: How does ixazomib affect symptoms and findings (severity, frequen-
cy) of multiple myeloma? 
The overall rates of response (ORR) were 78.3% (n = 282, ixazomib) and 
71.5% (n = 259, placebo); a complete response (CR) occurred in 42 patients 
(12%) in the ixazomib group and in 24 patients (7%) in the placebo group. 
240 patients (67%) in the ixazomib group and 235 (65%) in the placebo 
group showed partial responses (PR). Stable disease (SD) could be observed 
in 40 patients (11%) in the ixazomib group and in 59 patients (16%) of the 
placebo group. The median time to response was 1.1 and 1.9 months in pa-
tients receiving ixazomib and in patients receiving placebo respectively. The 
corresponding median duration of response was 20.5 months and 15.0 
months. 
 
 
median age of 66 and 
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D0011: What is the effect of ixazomib on patients̕ body functions? 
No evidence was found to answer this research question. 
 
D0012: What is the effect of ixazomib on generic health-related quality of 
life? 
D0013: What is the effect of ixazomib on disease-specific quality of life? 
At a median follow-up of about 23 months, patient-reported quality of life 
(QoL) was maintained with the addition of ixazomib to the treatment regi-
men lenalidomide-dexamethasone. A trend toward better physical function-
ing, emotional functioning and fatigue scores in the ixazomib group com-
pared to the placebo group could be observed. Nausea and vomiting symp-
toms were similar in both study groups and stable during treatment. Diar-
rhoea seemed to be worsening in later cycles of patients receiving ixazomib. 
However, no significant difference in QoL could be observed. 
 
Table 1: Efficacy results of the TOURMALINE-MM1 trial 
Descriptive statistics and 
estimate variability 
Treatment group 
Ixazomib-lenalidomide-
dexamethasone 
Placebo 
Number of subjects 360 362 
Median PFS (overall), 
months 
20.6 14.7 
Median PFS (HCR), 
months 21.4 9.7 
Median OS, months NR NR 
ORR, % 
CR 
PR 
SD 
78.3 
12 
67 
11 
71.5 
7 
65 
16 
Effect estimate per com-
parison Comparison groups 
Ixazomib-lenalidomide-
dexamethasone vs. place-
bo 
PFS (overall) HR 0.74 
95% CI 0.59–0.94 
Log-rank test p value 0.01 
PFS (HCR) HR 0.54 
95% CI 0.32–0.92 
Log-rank test p value 0.02 
Abbreviations: CI = confidence interval, CR = complete response, HR = hazard ratio, HCR = high cytogenetic risk 
patients, NR = not reached, ORR = overall response rate, OS = overall survival, PFS = progression-free survival, PR = 
partial response, SD = stable disease 
 
7.1.2 Safety 
C0008: How safe is ixazomib in relation to the comparator(s)? 
AEs of any grade were reported in 98% (ixazomib) and 99% (placebo) of pa-
tients. The most common AEs of any grade in the ixazomib group were diar-
rhoea (45%), rash (36%), constipation (35%), fatigue (29%) and nausea 
(29%).  
no significant  
difference in QoL 
any grade AEs 
ixazomib: 98% 
placebo: 99% 
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Grade ≥3 AEs could be observed in 74% of patients in the ixazomib group 
and in 69% of patients in the placebo group. Serious AEs occurred in 47% 
(ixazomib) and in 49% (placebo) of patients. Permanent discontinuation 
due to AEs of any agent occurred in 25% of patients in the ixazomib group 
and in 20% of patients in the placebo group. All common AEs and other AEs 
of clinical importance can be found in Table 2. 
 
C0002: Are the harms related to dosage or frequency of applying ixazomib? 
Dose reductions of any drug appeared in 56% of patients in the ixazomib 
group and in 50% of patients in the placebo group. Dose adjustments to 
manage symptoms occurred in regard to the management of diarrhoea and 
rash. 
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of ixazomib? 
Administration of ixazomib to pregnant woman can cause foetal harm based 
on earlier studies on animals. However, there are no controlled trials that 
have investigated ixazomib in pregnant women. Patients with hepatic im-
pairment or renal impairment should receive a reduced initial dose of ix-
azomib [2]. 
 
Table 2: Most frequent adverse events 
Adverse Event (according  
to CTCAE version 4.03) 
Ixazomib-lenalidomide-
dexamethasone (n = 361) 
Placebo (n = 359) 
 Any Grade  
n (%) 
Grade 3 
n (%) 
Grade 4 
n (%) 
Any Grade  
n (%) 
Grade 3 
n (%) 
Grade 4 
n (%) 
Common hematologic AEs of any cause* 
Neutropenia 118 (33) 64 (18) 17 (5) 111 (31) 63 (18) 22 (6) 
Thrombocytopenia 112 (31) 43 (12) 26 (7) 57 (16) 19 (5) 13 (4) 
Anaemia 103 (29) 34 (9) 0 (0) 98 (27) 48 (13) 0 (0) 
Common non-hematologic AEs of any cause* 
Diarrhoea 164 (45) 23 (6) 0 (0) 139 (39) 9 (3) 0 (0) 
Rash 
Standardised MedDRA query 
High-level term 
 
131 (36) 
72 (20) 
 
18 (5) 
9 (2) 
 
0 (0) 
0 (0) 
 
82 (23) 
45 (13) 
 
6 (2) 
6 (2) 
 
0 (0) 
0 (0) 
Constipation 126 (35) 1 (<1) 0 (0) 94 (26) 1 (<1) 0 (0) 
Fatigue 106 (29) 13 (4) 0 (0) 102 (28) 10 (3) 0 (0) 
Nausea 104 (29) 6 (2) 0 (0) 79 (22) 0 (0) 0 (0) 
Peripheral edema 101 (28) 8 (2) 0 (0) 73 (20) 4 (1) 0 (0) 
Peripheral neuropathy 97 (27) 9 (2) 0 (0) 78 (22) 6 (2) 0 (0) 
Back pain 87 (24) 3 (<1) 0 (0) 62 (17) 9 (3) 0 (0) 
Vomiting 84 (23) 4 (1) 0 (0) 42 (12) 2 (<1) 0 (0) 
Upper respiratory tract infection 83 (23) 2 (<1) 0 (0) 70 (19) 3 (<1) 0 (0) 
Nasopharyngitis 81 (22) 0 (0) 0 (0) 73 (20) 0 (0) 0 (0) 
Insomnia 73 (20) 7 (2) 0 (0) 98 (27) 11 (3) 0 (0) 
Muscle spasms 66 (18) 0 (0) 0 (0) 95 (26) 2 (<1) 0 (0) 
 
grade ≥3 AEs 
ixazomib: 74% 
placebo: 69% 
dose reductions 
ixazomib: 56% 
placebo: 50% 
reduced starting dosage 
of ixazomib in patients 
with renal and hepatic 
impairment 
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Other AEs of clinical interest 
ArrhythmiasA 56 (16) 17 (5) 3 (<1) 53 (15) 10 (3) 1 (<1) 
ThromboembolismA 29 (8) 9 (2) 2 (<1) 38 (11) 11 (3) 1 (<1) 
Liver impairment 26 (7) 7 (2) 0 (0) 21 (6) 4 (1) 0 (0) 
Hypertension 
Any 
Hypertension crisis 
 
22 (6) 
1 (<1) 
 
11 (3) 
0(0) 
 
0 (0) 
0 (0) 
 
18 (5) 
0 (0) 
 
4 (1) 
0 (0) 
 
0 (0) 
0 (0) 
HypotensionA 22 (6) 4 (1) 0 (0) 21 (6) 1 (<1) 0 (0) 
Heart failure 16 (4) 7 (2) 2 (<1) 14 (4) 4 (1) 2 (<1) 
Acute renal failureA 31 (9) 7 (2) 2 (<1) 41 (11) 12 (3) 4 (1) 
Myocardial infarctionA 5 (1) 0 (0) 3 (<1) 8 (2) 2 (<1) 2 (<1) 
Encephalopathy 2 (<1) 2 (<1) 0 (0) 4 (1) 0 (0) 0 (0) 
Interstitial lung disease  4 (1) 1 (<1) 1 (<1) 7 (2) 2 (<1) 0 (0) 
New primary malignant tumour 17 (5) NA NA 14 (4) NA NA 
Abbreviations: 
A
 = reported grade 5 AEs: arrhythmia was reported in two patients in the ixazomib group and in three in the 
placebo group, thromboembolism was reported in one patient in each group, hypotension was reported in one patient in the 
ixazomib group, heart failure was reported in one patient in the ixazomib group and in three patients in the placebo group, 
myocardial infarction was reported in one patient in the ixazomib group and in two patients in the placebo group; AEs = adverse 
events; MedDRA = Medical Dictionary for Regulatory Activities; NA = not applicable; * = AEs reported in at least 20% of 
patients in either group. 
 
7.2 Clinical effectiveness and safety –  
Further studies 
An open-label, non-randomised, phase I/II trial [25] was conducted to assess 
the safety, tolerability, and activity of weekly oral ixazomib combined with 
lenalidomide and low-dose dexamethasone in patients with newly diagnosed 
MM. Included were 65 newly diagnosed MM patients (15 in phase I and 50 
in phase II). To establish the recommended dose of ixazomib, patients re-
ceived escalating doses of ixazomib (1.68–3.95 mg/m²) in phase I of the 
study. In phase II of the study, enrolled patients received 2.23 mg/m² of oral 
ixazomib (days 1, 8, 15) plus 25 mg of lenalidomide (days 1–21) and 40 mg 
of dexamethasone (days 1, 8, 15, 22) for up to twelve 28-day cycles, followed 
by maintenance therapy with ixazomib alone. The primary endpoints were 
the maximum tolerated dose of ixazomib (phase I), and the rate of very good 
partial response or better (phase II). Secondary outcomes were safety, the 
characterisation of the pharmacokinetics of ixazomib, and the evaluation of 
response rates. 
One dose-limiting toxic event in phase I was noted at a dose of 2.97 mg/m² 
of ixazomib and three events at 3.95 mg/m². The maximum tolerated dose of 
ixazomib was defined at 2.97 mg/m². In addition, based on population 
pharmacokinetic results the recommended phase II fixed dose of ixazomib 
was 4.0 mg (2.23 mg/m²). Drug-related grade ≥ 3 AEs were reported in 41 
(63%) patients, including skin and subcutaneous tissue disorders (17%), 
neutropenia (12%), and thrombocytopenia (8%). Grade 3 or higher drug-
related peripheral neuropathy occurred in four (6%) patients. Five patients 
discontinued because of AEs. 58% (95% CI 45–70) of patients had at least a 
very good partial response.  
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combination with 
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dose dexamethasone 
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fixed dose 4.0 mg 
 
 
grade ≥ 3 AEs related to 
any drug: 
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8 Estimated costs 
A0021: What is the reimbursement status of ixazomib? 
In Austria, ixazomib is available as 2.3, 3, and 4-mg hard capsules in pack-
ages of 3 pieces each at € 8,572.3 [27]. The recommended dose of ixazomib is 
4 mg orally on days 1,8 and 15 of a 28-day cycle. According to this dosing 
recommendation, the costs for a 28-day treatment cycle would be € 8,572.3. 
Costs for about 17 treatment cycles may occur, since in the TOURMALINE-
MM1 trial [23] patients received 17 (1–34) and 15 (1–34) treatment cycles in 
the ixazomib group and in the placebo group, respectively. Additional costs 
for lenalidomide and dexamethasone would arise for the triplet combination 
treatment. 
 
 
 
9 Ongoing research 
In November 2016 a search in databases http://clinicaltrials.gov/ and 
https://www.clinicaltrialsregister.eu/ctr-search/ was conducted. The fol-
lowing ongoing phase III trials are investigating ixazomib in different re-
gimes in patients with MM: 
 NCT02181413: A phase III, randomised, placebo-controlled, dou-
ble-blind study of oral ixazomib citrate (MLN9708) maintenance 
therapy in patients with multiple myeloma following autologous 
stem cell transplant. Estimated study completion date is July 2023. 
 NCT02312258: A phase III, randomised, placebo-controlled, dou-
ble-blind study of oral ixazomib maintenance therapy after initial 
therapy in patients with newly diagnosed multiple myeloma not 
treated with stem cell transplantation. Estimated study completion 
date is July 2019. 
 NCT01850524: A phase III, randomised, double-blind, multicentre 
study comparing oral ixazomib (MLN9708) plus lenalidomide and 
dexamethasone versus placebo plus lenalidomide and dexame-
thasone in adult patients with newly diagnosed multiple myeloma. 
Estimated study completion date is February 2021. 
Various phase I and II studies are currently ongoing in different treatment 
lines in patients with MM, using ixazomib in different regimes (e.g. 
NCT02477215, NCT01217957, NCT02004275, NCT01383928, 
NCT02057640, NCT02057640, and NCT02542657) In addition, ixazomib is 
also currently being investigated for other indications such as mantle cell 
lymphoma, renal cell carcinoma, non-Hodgkin lymphoma, follicular lym-
phoma and acute myeloid leukaemia. 
 
 
 
estimated costs for 28-
day treatment cycle of 
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treatment lines 
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10 Discussion 
On 20 November 2015 ixazomib, in combination with lenalidomide and 
dexamethasone, was approved by the FDA for the treatment of patients with 
MM who have received at least one prior therapy [2]. The EMA has granted 
marketing authorisation to ixazomib in November 2016 for the combination 
therapy with lenalidomide and dexamethasone in adult patients with MM 
who have received at least one prior therapy [6]. 
The FDA approval was based on the interim results of three study endpoints 
of the TOURMALINE-MM1 [23, 24] trial, a randomised, double-blind, mul-
ticentre, placebo-controlled phase III study. 722 previously treated patients 
were randomised in a 1:1 ratio to either receive ixazomib in combination 
with lenalidomide and dexamethasone or placebo in combination with le-
nalidomide and dexamethasone. The primary endpoint PFS showed a signif-
icant increase of 5.9 months (median) compared to the placebo arm. ORR 
was also significantly improved among patients who received ixazomib 
combination therapy: 78.3% in the ixazomib group versus 71.5% in the pla-
cebo group. However, median OS had not yet been reached in either study 
group; the follow-up, however, is ongoing. 
In terms of safety, grade 3–4 AEs occurred more often (+5%) in the ixazo-
mib group than in the placebo arm. The most frequent AEs of any grade in 
the ixazomib group were diarrhoea, rash, constipation, fatigue and nausea. 
Permanent discontinuation due to AEs of any agent occurred more common-
ly (+5%) in the ixazomib group. QoL was maintained with the addition of 
ixazomib to the treatment regimen of lenalidomide-dexamethasone. 
Since only results based on the interim analysis of the trial are available, a 
lack of data in long-term efficacy and safety exists. Thus, further follow-up 
of the study population is required especially because median OS was not 
reached in either treatment arm. In terms of safety, the potential occurrence 
of late side effects, as well as long-term effects on QoL, needs to be evaluat-
ed. 
Although a positive difference in median PFS in the intention-to-treat popu-
lation could be observed, the subgroup analysis showed that patients be-
tween 65 and 75 years of age do not benefit from the ixazomib regimen (17.5 
vs. 17.6 months). This patient group is of high importance, because myeloma 
is most frequently diagnosed between the ages of 65 and 74 (median age 69) 
[12]. 
Patients with high-risk cytogenetic abnormalities showed a greater positive 
difference in median PFS than the intention-to-treat population (11.7 vs. 5.9 
months). This patient population should be further investigated, since MM 
is characterised by chromosomal instability, and cytogenetic abnormalities 
have an effect on prognosis [28]. 
Two other triplet combination regimens with lenalidomide and dexame-
thasone for the treatment of MM have received marketing authorisation 
from the EMA and the FDA since 2015. One of the approved treatment reg-
imens included the proteasome inhibitor carfilzomib. This treatment option 
was investigated in the phase III trial ASPIRE [29], in which a significant 
improvement in median PFS compared to the control arm (26.3 vs. 17.6 
months, 8.7 months gain) was shown. However, no results for OS are availa-
ble at the moment. The other approved regimen was a combination regimen 
positive CHMP opinion 
in Europe, licensed in 
the USA 
TOURMALINE-MM 
(interim analysis): 
significantly improved 
PFS and ORR, but OS 
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with a monoclonal antibody, elotuzumab. This antibody was examined in 
the ELOQUENT-2 trial [30]. In this phase III study a significant increase in 
median PFS in the intervention arm compared to the control arm could be 
observed (19.4 vs. 14.9 months, 4.5 months gain). Nevertheless, no mature 
data for OS was also available in this trial. 
Direct comparison of the ixazomib regimen to the two already approved reg-
imens (carfilzomib and elotuzumab) with lenalidomide and dexamethasone 
are needed to investigate which treatment option MM patients benefit the 
most from. Furthermore, subgroup analysis in these comparative trials for 
patients with high-risk cytogenetic abnormalities as well as older patients 
(> 65 years) would be of high relevance. In addition, the comparison of toxic 
effects of these treatments, should be compared since patients treated carfil-
zomib in clinical trials have been associated with a ~5% incidence of unex-
plained and unpredictable cardiovascular toxicity as well as ixazomib treat-
ed patients show increased neurotoxicity’s. Indirect trial comparisons are in-
sufficient, due to differences in the study designs, patient populations and 
methods. 
The costs per 28-day treatment cycle would be € 8,572.3 [27]. Costs for about 
17 treatment cycles may arise, since the median number of treatment cycles 
in the ixazomib group were 17 (1-34) and 15 (1-34) in the placebo group. 
Moreover, additional costs for the treatment of AEs as well as the combina-
tion therapies (lenalidomide and dexamethasone) would arise in all men-
tioned triplet combination regimes. 
In conclusion, the treatment with ixazomib in combination with lenalido-
mide and dexamethasone offers a significant improvement in PFS (median 
gain 5.9 months, intention-to-treat population), even for patients with high-
risk cytogenetic abnormalities. However, the missing data for OS and the 
lack of benefit for the actual patient population most affected by MM in 
clinical practice (> 65 years) highlight the requirement for long-term data. 
Finally, the direct comparison of ixazomib to the carfilzomib and elo-
tuzumab triplet combination regimens is necessary to identify the best 
treatment option for MM patients who received prior therapies. 
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12 Appendix  
Table 3: Characteristics of the TOURMALINE-MM1 trial 
Title: Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma [23, 24] 
Study identifier NCT01564537, EudraCT number 2011-005496-17, TOURMALINE-MM1 
Design Phase III, randomised, multicentre, placebo-controlled, double-blind trial 
Duration Data cut-off of the 1
st analysis: 30 October 2014 
Median follow-up of the 1st analysis: 14.8 months (ixazo-
mib), 14.6 months (placebo) 
 
Data cut-off of subsequent analysis: 12 July 2015 
Median follow-up of subsequent analysis: 23 months 
 
 
Hypothesis 
Superiority 
The study was designed to show a prolonged PFS in patients treated with ixazomib plus lenalido-
mide and dexamethasone compared to those who received placebo plus lenalidomide and dexame-
thasone. The primary endpoint (PFS) was based on central laboratory results and International 
Myeloma Working Group 11 criteria and evaluated by an independent review committee, with 
80% power at a two-sided alpha level of 0.05. 
Funding Millennium Pharmaceuticals, Inc. (Takeda Oncology) 
Treatments groups 
Intervention (n = 360) 
Oral ixazomib was administered at a dose of 4 mg on days 
1, 8 and 15 of a 28-day treatment cycle. Oral lenalidomide 
was administered at a dose of 25 mg on days 1 through 21 
and on days 1, 8, 15 and 22 patients additionally received 
40 mg of dexamethasone. 
Control (n = 362) 
Placebo was administered on days 1, 8 and 15 of a 28-day 
treatment cycle. Additionally, patients received 25 mg of 
oral lenalidomide on days 1 through 21 and 40 mg of dex-
amethasone on days 1, 8, 15 and 22. 
Endpoints and definitions Progression-free survival 
(primary outcome) PFS 
Time from the date of randomisation to the date of first 
documentation of disease progression or death from any 
cause, as assessed by an independent review committee. 
Overall survival OS Defined as the time from the date of randomisation to the date of death. 
overall response rate ORR 
Defined as the percentage of participants with complete 
response (CR) including stringent complete response 
(sCR), very good partial response (VGPR) and partial re-
sponse (PR) assessed by the IRC using IMWG criteria. 
Results and Analysis  
Analysis description Primary Analysis 
All primary and secondary efficacy analyses were performed in the intention-to-treat population 
(all patients who underwent randomisation). For the safety analysis all patients who received at 
least one dose of a study drug or placebo were investigated. 
Analysis population  
 
 
 
 
 
Inclusion 
 Male or female participants 18 years of age or older 
 Relapsed, refractory, primary refractory or relapsed and refractory 
MM 
 Measurable levels of disease  
 ECOG performance status score of 0 to 2 
 One to three prior therapies 
 Adequate hematologic and hepatic function 
 Mild-to-moderate impairment of renal function 
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Title: Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma [23, 24] 
Study identifier NCT01564537, EudraCT number 2011-005496-17, TOURMALINE-MM1 
Analysis population 
(continuation) 
 
 
Exclusion 
 Peripheral neuropathy of grade 1 with pain or grade 2 or higher or 
had disease that was refractory to prior lenalidomide therapy or 
proteasome inhibitor-based therapy 
 Patients who have failed to recover from effects of prior chemo-
therapy 
 Any central nervous system involvement 
 Evidence of current uncontrolled cardiovascular conditions 
 Comorbid systematic illness or other severe concurrent disease 
 Patients were excluded for the following reasons (within 14 days 
before randomisation):  
- undergone major surgery 
- received radiotherapy 
- had an infection requiring systematic antibiotic therapy or other 
serious infections 
- had received systematic treatment with strong CYP1A2, strong 
CYP3A inhibitors or strong CYP3A inducers or had used Ginko biloba 
or St. John's wort 
 
Characteristics 
 
Intervention 
(n = 360) 
Control 
(n = 362) 
Median age (range), years 
>65, n (%) 
66 (38–91) 
192 (53) 
66 (30–89) 
186 (51) 
Gender, n (%) 
♂ 207 (58) 
♀ 153 (42) 
♂ 202 (56) 
♀ 160 (44) 
White race, n (%) 310 (86) 301 (83) 
ECOG performance status,  
n/total (%) 
0 
1 
2 
 
 
180/354 (51) 
156/354 (44) 
18/354 (5) 
 
 
170/358 (47) 
164/358 (46) 
24/358 (7) 
ISS disease stage at study entry, n (%) 
I 
II 
III 
 
226 (63) 
89 (25) 
45 (12) 
 
233 (64) 
87 (24) 
42 (12) 
Median time since initial diagnosis of MM (range), 
months 44.2 (3–281) 42.2 (4–306) 
Cytogenetic features, n (%) 
Standard-risk 
High-risk 
Data not available 
 
199 (55) 
75 (21) 
86 (24) 
 
216 (60) 
62 (17) 
84 (23) 
Number of prior therapies, n (%) 
1 
2 
3 
 
224 (62) 
97 (27) 
39 (11) 
 
217 (60) 
111 (31) 
34 (9) 
Disease category, n/total (%) 
Relapsed 
Refractory 
Relapsed and Refractory  
Primary refractory 
 
276/359 (77) 
42/359 (12) 
41/359 (11) 
24/359 (7) 
 
280/362 (77) 
40/362 (11) 
42/362 (12) 
22/362 (6) 
Prior proteasome inhibitor therapy, n (%) 
Bortezomib 
Carfilzomib 
 
248 (69) 
1 (<1) 
 
250 (69) 
4 (1) 
Disease refractory to any prior therapy,  
n (%) 4 (1) 8 (2) 
 Prior immunomodulatory drug therapy, n/total (%) 
Lenalidomide 
Thalidomide 
Disease refractory to any prior immunomodulatory 
drug therapy 
193/360 (54) 
 
44/360 (12) 
157/360 (44) 
41/193 (21) 
204/362 (56) 
 
44/362 (12) 
170/362 (47) 
50/204 (25) 
Abbreviations: ECOG = Eastern Cooperative Oncology Group, IMWG = International Myeloma Working Group, IRC = Independent Review 
Committee, MM = multiple myeloma 
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Table 4: Risk of bias assessment on study level is based on EUnetHTA (Internal validity of randomised controlled trials) 
[26] 
Criteria for judging risk of bias  risk of bias 
Adequate generation of randomisation sequence: no information available unclear 
Adequate allocation concealment: no information available unclear 
Blinding: 
double-blind 
Patient yes 
Treating Physician yes 
Selective outcome reporting unlikely: confidence intervals of the median PFS values for 
both treatment arms are not available 
no 
No other aspects which increase the risk of bias: no aspects which increase the risk of bias 
were found 
yes 
Risk of bias – study level low 
 
